Sort   by:  
 Page size 
GenomicsRAG1 targeting in the genome is dominated by chromatin interactions mediated by the non-core regions of RAG1 and RAG2
The RAG1/RAG2 endonuclease initiates V(D)J recombination at antigen receptor loci but also binds to thousands of places outside of these loci. RAG2 localizes directly to lysine 4 trimethylated histone 3 (H3K4me3) through a PHD finger. The relative contribution of RAG2-dependent and RAG1-intrinsic ...
ORGANISM(S): Homo sapiens 
2016-07-06 | E-GEOD-84052 | biostudies-arrayexpress
GenomicsHistone Reader BRWD1 Targets and Restricts Recombination to the Igk Locus
B lymphopoiesis requires that immunoglobulin genes be accessible to RAG1-RAG2 recombinase. However, the RAG proteins bind widely to open chromatin, which suggests that additional mechanisms must restrict RAG-mediated DNA cleavage. Here we show that developmental downregulation of interleukin 7 (IL-7...
ORGANISM(S): Mus musculus 
2015-08-24 | E-GEOD-63302 | biostudies-arrayexpress
GenomicsRAG Represents a Widespread Threat to the Lymphocyte Genome - (ChIP-seq)
The RAG1 endonuclease, together with its cofactor RAG2, is essential for V(D)J recombination but is a potent threat to genome stability. The sources of RAG1 mistargeting and the mechanisms that have evolved to suppress it are poorly understood. Here, we report the surprising finding that RAG1 bind...
ORGANISM(S): Mus musculus 
2015-08-06 | E-GEOD-69475 | biostudies-arrayexpress
GenomicsRAG Represents a Widespread Threat to the Lymphocyte Genome - (Mnase-seq)
The RAG1 endonuclease, together with its cofactor RAG2, is essential for V(D)J recombination but is a potent threat to genome stability. The sources of RAG1 mistargeting and the mechanisms that have evolved to suppress it are poorly understood. Here, we report the surprising finding that RAG1 bind...
ORGANISM(S): Mus musculus 
2015-08-06 | E-GEOD-69474 | biostudies-arrayexpress
UnknownEffects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Not available
S-EPMC7615591 | biostudies-literature
UnknownFrailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Not available
S-EPMC11390031 | biostudies-literature
UnknownImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Not available
S-EPMC7618536 | biostudies-literature
UnknownEffects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Not available
S-EPMC12274867 | biostudies-literature
UnknownDonepezil delays progression to AD in MCI subjects with depressive symptoms.
Not available
S-EPMC2697965 | biostudies-literature
UnknownLong-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7616743 | biostudies-literature
Sort   by:  
 Page size